Financing co-led by RA Capital Management, Fidelity Management & Research Company, and Janus Henderson Investors CAMBRIDGE, Mass.–(BUSINESS WIRE)–Parabilis MedicinesFinancing co-led by RA Capital Management, Fidelity Management & Research Company, and Janus Henderson Investors CAMBRIDGE, Mass.–(BUSINESS WIRE)–Parabilis Medicines

Parabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical Development Across a Broad Range of Tumors and Advance Pioneering Pipeline and Helicon Platform

Financing co-led by RA Capital Management, Fidelity Management & Research Company, and Janus Henderson Investors

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer using its Helicon™ peptide platform to drug historically undruggable targets, today announced the successful closing of a $305 million Series F financing.

The round was co-led by RA Capital Management, Fidelity Management & Research Company and Janus Henderson Investors, with participation from new investors including Frazier Life Sciences, Soleus Capital, and a life science-dedicated investment fund. There was also strong participation from existing investors, including venBio Partners, Cormorant Asset Management, Nextech Invest, ARCH Venture Partners, Milky Way Investments, GV, accounts advised by T. Rowe Price Associates, Inc., Marshall Wace, General Catalyst, Invus, Farallon Capital Management, Foresite Capital, Rock Springs Capital, HBM Healthcare, Samsara BioCapital, Catalio Capital Management, Sixty Degree Capital, Alderline Group and others. The financing was completed at an increased valuation relative to the company’s prior financing.

The financing will support the continued clinical development of FOG-001 (zolucatetide) – the company’s lead investigational Helicon peptide and first and only direct inhibitor of the elusive β-catenin:TCF interaction – including progression toward a registrational trial in desmoid tumors and continued evaluation across a range of genetically simple and more complex tumor types. The financing will also support the progression of the company’s targeted discovery pipeline, including its promising prostate cancer franchise, and additional efforts to leverage the company’s Helicon platform to unlock disease targets long considered “undruggable.”

“Our goal at Parabilis is to develop medicines with the potential to deliver truly life-changing impact for patients who urgently need new treatment options,” said Mathai Mammen, M.D., Ph.D., Chairman, CEO and President of Parabilis Medicines. “We are deeply grateful for the support and confidence of our world-class investors, which will enable us to advance zolucatetide across a range of rare and common tumor types – creating the opportunity for a pipeline within a product – while continuing to build a unique and differentiated pipeline through our Helicon platform designed to address biology that has remained out of reach for decades.”

This financing follows presentations of compelling preliminary data in the fourth quarter of 2025 from Parabilis’s ongoing Phase 1/2 trial of zolucatetide, a first-in-class therapy targeting the key downstream node within the Wnt/β-catenin pathway. This pathway is implicated in millions of cancer cases annually yet remains unaddressed by any approved therapies.

Early data demonstrated meaningful single-agent activity of zolucatetide across five low complexity tumor types driven by Wnt/β-catenin alterations – including desmoid tumors, an indication granted Fast Track Designation from the U.S. Food & Drug Administration, and adamantinomatous craniopharyngioma (ACP). The findings also showed strong scientific rationale for combination approaches in more biologically complex cancers, including microsatellite-stable colorectal cancer (MSS CRC). At next week’s J.P. Morgan Healthcare Conference, Parabilis will share additional data in desmoid tumors, as well as early clinical evidence of zolucatetide’s potential in hepatocellular carcinoma (HCC) and familial adenomatous polyposis (FAP). Parabilis plans to provide additional data readouts in 2026.

In parallel, Parabilis continues to demonstrate the broad applicability of its Helicon platform beyond zolucatetide, with encouraging data from its preclinical Helicon degrader programs targeting ERG and allosteric ARON, two historically intractable targets in prostate cancer. Together, these programs highlight the platform’s ability to repeatedly generate multiple differentiated therapeutic candidates against high-value targets.

“Successfully drugging a target long considered undruggable requires both deep biological insight and a differentiated technological approach. With Helicons, Parabilis has established a platform with the potential to generate a robust pipeline of impactful therapies,” said Jake Simson, Ph.D., Partner at RA Capital. “We believe this financing positions the Parabilis team to build enduring value by translating the company’s recent data and breakthroughs into multiple development opportunities.”

Despite decades of progress, the vast majority of the human proteome remains “undruggable” with today’s modalities. Many key disease drivers are intracellular—out of reach for antibodies—and have only flat protein surfaces that small molecules can’t effectively bind. Parabilis’s α-helical Helicon peptides, designed based on the pioneering work of Greg Verdine, are engineered to overcome these limitations, creating a new path to selectively engage disease-driving targets long considered out of reach.

About Parabilis Medicines

Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines that unlock high-impact protein targets long-considered undruggable. Leveraging over a decade of proprietary data, laboratory innovations, and AI- and physics-based algorithms, the company has developed a new class of stabilized, cell-penetrant alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that are inaccessible to traditional drug modalities.

Headquartered in Cambridge, Mass., Parabilis is advancing a focused pipeline of multiple first-in-class therapies across both rare and common cancers. Its lead candidate, FOG-001 (zolucatetide), is the first direct inhibitor of the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors, implicated in colorectal cancer, desmoid tumors, and a range of other Wnt/β-catenin-driven tumors. Parabilis is also advancing investigational degraders of ERG and allosteric ARON for the treatment of prostate cancer, as well as other preclinical programs.

Learn more about how the company is advancing a new generation of precision cancer medicines with the potential to meaningfully alter the trajectory of disease for patients in need: www.parabilismed.com.

Contacts

Media Contact for Parabilis
Ten Bridge Communications

Nichole Bobbyn

nichole@tenbridgecommunications.com

Market Opportunity
FOGNET Token Logo
FOGNET Token Price(FOG)
$0.01403
$0.01403$0.01403
-3.90%
USD
FOGNET Token (FOG) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

21Shares Launches JitoSOL Staking ETP on Euronext for European Investors

21Shares Launches JitoSOL Staking ETP on Euronext for European Investors

21Shares launches JitoSOL staking ETP on Euronext, offering European investors regulated access to Solana staking rewards with additional yield opportunities.Read
Share
Coinstats2026/01/30 12:53
Digital Asset Infrastructure Firm Talos Raises $45M, Valuation Hits $1.5 Billion

Digital Asset Infrastructure Firm Talos Raises $45M, Valuation Hits $1.5 Billion

Robinhood, Sony and trading firms back Series B extension as institutional crypto trading platform expands into traditional asset tokenization
Share
Blockhead2026/01/30 13:30
Summarize Any Stock’s Earnings Call in Seconds Using FMP API

Summarize Any Stock’s Earnings Call in Seconds Using FMP API

Turn lengthy earnings call transcripts into one-page insights using the Financial Modeling Prep APIPhoto by Bich Tran Earnings calls are packed with insights. They tell you how a company performed, what management expects in the future, and what analysts are worried about. The challenge is that these transcripts often stretch across dozens of pages, making it tough to separate the key takeaways from the noise. With the right tools, you don’t need to spend hours reading every line. By combining the Financial Modeling Prep (FMP) API with Groq’s lightning-fast LLMs, you can transform any earnings call into a concise summary in seconds. The FMP API provides reliable access to complete transcripts, while Groq handles the heavy lifting of distilling them into clear, actionable highlights. In this article, we’ll build a Python workflow that brings these two together. You’ll see how to fetch transcripts for any stock, prepare the text, and instantly generate a one-page summary. Whether you’re tracking Apple, NVIDIA, or your favorite growth stock, the process works the same — fast, accurate, and ready whenever you are. Fetching Earnings Transcripts with FMP API The first step is to pull the raw transcript data. FMP makes this simple with dedicated endpoints for earnings calls. If you want the latest transcripts across the market, you can use the stable endpoint /stable/earning-call-transcript-latest. For a specific stock, the v3 endpoint lets you request transcripts by symbol, quarter, and year using the pattern: https://financialmodelingprep.com/api/v3/earning_call_transcript/{symbol}?quarter={q}&year={y}&apikey=YOUR_API_KEY here’s how you can fetch NVIDIA’s transcript for a given quarter: import requestsAPI_KEY = "your_api_key"symbol = "NVDA"quarter = 2year = 2024url = f"https://financialmodelingprep.com/api/v3/earning_call_transcript/{symbol}?quarter={quarter}&year={year}&apikey={API_KEY}"response = requests.get(url)data = response.json()# Inspect the keysprint(data.keys())# Access transcript contentif "content" in data[0]: transcript_text = data[0]["content"] print(transcript_text[:500]) # preview first 500 characters The response typically includes details like the company symbol, quarter, year, and the full transcript text. If you aren’t sure which quarter to query, the “latest transcripts” endpoint is the quickest way to always stay up to date. Cleaning and Preparing Transcript Data Raw transcripts from the API often include long paragraphs, speaker tags, and formatting artifacts. Before sending them to an LLM, it helps to organize the text into a cleaner structure. Most transcripts follow a pattern: prepared remarks from executives first, followed by a Q&A session with analysts. Separating these sections gives better control when prompting the model. In Python, you can parse the transcript and strip out unnecessary characters. A simple way is to split by markers such as “Operator” or “Question-and-Answer.” Once separated, you can create two blocks — Prepared Remarks and Q&A — that will later be summarized independently. This ensures the model handles each section within context and avoids missing important details. Here’s a small example of how you might start preparing the data: import re# Example: using the transcript_text we fetched earliertext = transcript_text# Remove extra spaces and line breaksclean_text = re.sub(r'\s+', ' ', text).strip()# Split sections (this is a heuristic; real-world transcripts vary slightly)if "Question-and-Answer" in clean_text: prepared, qna = clean_text.split("Question-and-Answer", 1)else: prepared, qna = clean_text, ""print("Prepared Remarks Preview:\n", prepared[:500])print("\nQ&A Preview:\n", qna[:500]) With the transcript cleaned and divided, you’re ready to feed it into Groq’s LLM. Chunking may be necessary if the text is very long. A good approach is to break it into segments of a few thousand tokens, summarize each part, and then merge the summaries in a final pass. Summarizing with Groq LLM Now that the transcript is clean and split into Prepared Remarks and Q&A, we’ll use Groq to generate a crisp one-pager. The idea is simple: summarize each section separately (for focus and accuracy), then synthesize a final brief. Prompt design (concise and factual) Use a short, repeatable template that pushes for neutral, investor-ready language: You are an equity research analyst. Summarize the following earnings call sectionfor {symbol} ({quarter} {year}). Be factual and concise.Return:1) TL;DR (3–5 bullets)2) Results vs. guidance (what improved/worsened)3) Forward outlook (specific statements)4) Risks / watch-outs5) Q&A takeaways (if present)Text:<<<{section_text}>>> Python: calling Groq and getting a clean summary Groq provides an OpenAI-compatible API. Set your GROQ_API_KEY and pick a fast, high-quality model (e.g., a Llama-3.1 70B variant). We’ll write a helper to summarize any text block, then run it for both sections and merge. import osimport textwrapimport requestsGROQ_API_KEY = os.environ.get("GROQ_API_KEY") or "your_groq_api_key"GROQ_BASE_URL = "https://api.groq.com/openai/v1" # OpenAI-compatibleMODEL = "llama-3.1-70b" # choose your preferred Groq modeldef call_groq(prompt, temperature=0.2, max_tokens=1200): url = f"{GROQ_BASE_URL}/chat/completions" headers = { "Authorization": f"Bearer {GROQ_API_KEY}", "Content-Type": "application/json", } payload = { "model": MODEL, "messages": [ {"role": "system", "content": "You are a precise, neutral equity research analyst."}, {"role": "user", "content": prompt}, ], "temperature": temperature, "max_tokens": max_tokens, } r = requests.post(url, headers=headers, json=payload, timeout=60) r.raise_for_status() return r.json()["choices"][0]["message"]["content"].strip()def build_prompt(section_text, symbol, quarter, year): template = """ You are an equity research analyst. Summarize the following earnings call section for {symbol} ({quarter} {year}). Be factual and concise. Return: 1) TL;DR (3–5 bullets) 2) Results vs. guidance (what improved/worsened) 3) Forward outlook (specific statements) 4) Risks / watch-outs 5) Q&A takeaways (if present) Text: <<< {section_text} >>> """ return textwrap.dedent(template).format( symbol=symbol, quarter=quarter, year=year, section_text=section_text )def summarize_section(section_text, symbol="NVDA", quarter="Q2", year="2024"): if not section_text or section_text.strip() == "": return "(No content found for this section.)" prompt = build_prompt(section_text, symbol, quarter, year) return call_groq(prompt)# Example usage with the cleaned splits from Section 3prepared_summary = summarize_section(prepared, symbol="NVDA", quarter="Q2", year="2024")qna_summary = summarize_section(qna, symbol="NVDA", quarter="Q2", year="2024")final_one_pager = f"""# {symbol} Earnings One-Pager — {quarter} {year}## Prepared Remarks — Key Points{prepared_summary}## Q&A Highlights{qna_summary}""".strip()print(final_one_pager[:1200]) # preview Tips that keep quality high: Keep temperature low (≈0.2) for factual tone. If a section is extremely long, chunk at ~5–8k tokens, summarize each chunk with the same prompt, then ask the model to merge chunk summaries into one section summary before producing the final one-pager. If you also fetched headline numbers (EPS/revenue, guidance) earlier, prepend them to the prompt as brief context to help the model anchor on the right outcomes. Building the End-to-End Pipeline At this point, we have all the building blocks: the FMP API to fetch transcripts, a cleaning step to structure the data, and Groq LLM to generate concise summaries. The final step is to connect everything into a single workflow that can take any ticker and return a one-page earnings call summary. The flow looks like this: Input a stock ticker (for example, NVDA). Use FMP to fetch the latest transcript. Clean and split the text into Prepared Remarks and Q&A. Send each section to Groq for summarization. Merge the outputs into a neatly formatted earnings one-pager. Here’s how it comes together in Python: def summarize_earnings_call(symbol, quarter, year, api_key, groq_key): # Step 1: Fetch transcript from FMP url = f"https://financialmodelingprep.com/api/v3/earning_call_transcript/{symbol}?quarter={quarter}&year={year}&apikey={api_key}" resp = requests.get(url) resp.raise_for_status() data = resp.json() if not data or "content" not in data[0]: return f"No transcript found for {symbol} {quarter} {year}" text = data[0]["content"] # Step 2: Clean and split clean_text = re.sub(r'\s+', ' ', text).strip() if "Question-and-Answer" in clean_text: prepared, qna = clean_text.split("Question-and-Answer", 1) else: prepared, qna = clean_text, "" # Step 3: Summarize with Groq prepared_summary = summarize_section(prepared, symbol, quarter, year) qna_summary = summarize_section(qna, symbol, quarter, year) # Step 4: Merge into final one-pager return f"""# {symbol} Earnings One-Pager — {quarter} {year}## Prepared Remarks{prepared_summary}## Q&A Highlights{qna_summary}""".strip()# Example runprint(summarize_earnings_call("NVDA", 2, 2024, API_KEY, GROQ_API_KEY)) With this setup, generating a summary becomes as simple as calling one function with a ticker and date. You can run it inside a notebook, integrate it into a research workflow, or even schedule it to trigger after each new earnings release. Free Stock Market API and Financial Statements API... Conclusion Earnings calls no longer need to feel overwhelming. With the Financial Modeling Prep API, you can instantly access any company’s transcript, and with Groq LLM, you can turn that raw text into a sharp, actionable summary in seconds. This pipeline saves hours of reading and ensures you never miss the key results, guidance, or risks hidden in lengthy remarks. Whether you track tech giants like NVIDIA or smaller growth stocks, the process is the same — fast, reliable, and powered by the flexibility of FMP’s data. Summarize Any Stock’s Earnings Call in Seconds Using FMP API was originally published in Coinmonks on Medium, where people are continuing the conversation by highlighting and responding to this story
Share
Medium2025/09/18 14:40